Company / R&D Expense
ARS Pharmaceuticals, Inc. R&D Expense History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$13.2M
FY2025
5-year range
$13.2M / $20.3M
FY2021-FY2025
Trend
-32.7%
vs FY2024
Sector context
#203 of 210
Health Care
What the data says
Among 210 Health Care companies, ARS Pharmaceuticals, Inc. is in the bottom 3% for r&d expense. R&D Expense has declined for 3 consecutive years, from $20M in FY2022 to $13M in FY2025.
Based on SEC 10-K filings.
$13M in FY2025 with a 5-year CAGR of -11.7%.
Declined from $20M to $13M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -13.4%
- 5-Year CAGR
- -11.7%
- 10-Year CAGR
- -
Sector benchmark
Bottom 3% in Health CareTop 97% of 210This company $13.2M Sector average $644.1M
▼
-98.0% below sector average
Key checks
Key Insights
- ARS Pharmaceuticals, Inc.'s r&d expense has declined for 3 consecutive years.
- 5-year CAGR of -11.7%, indicating a declining trend.
- In FY2025, r&d expense decreased 32.7% year-over-year.
- Ranks #203 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.44 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $13.2M | -32.7% |
| FY2024 | $19.6M | -3.4% |
| FY2023 | $20.3M | -0.0% |
| FY2022 | $20.3M | +0.0% |
| FY2021 | $20.3M | -17.5% |
| FY2020 | $24.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026